HCC
NBSE

Hirtle Callaghan & Co’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Hirtle Callaghan & Co’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-6
Closed -$18K – 382
2014
Q4 		$18K Hold
6
– – ﹤0.01% 390
2014
Q3 		$16K Hold
6
– – ﹤0.01% 434
2014
Q2 		$21K Hold
6
– – ﹤0.01% 458
2014
Q1 		$32K Buy
+6
New +$31.6K 0.01% 403

Other funds holding NBSE

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TI
Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Hirtle Callaghan & Co's NBSE Position: Q1 2015 in Review

Hirtle Callaghan & Co sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2015, closing a stake of 6 shares — an estimated $18K sold.

Hirtle Callaghan & Co first reported a position in NBSE in Q1 2014 and held it in 4 quarters. The position peaked at $32K in Q1 2014. 64 funds tracked by Wall St. Rank hold NBSE as of Q1 2015.

  • Hirtle Callaghan & Co reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2015 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 6 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2015, an estimated $18K.
  • Hirtle Callaghan & Co first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2014 and held it in 4 quarters.
  • Hirtle Callaghan & Co's NeuBase Therapeutics, Inc. Common Stock position peaked at $32K in Q1 2014.
  • 64 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2015.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2015, filed 15 May 2015.